HemaCare Corporation Stock

HEMA

US4234981045

Healthcare Facilities & Services

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+0.08%	+0.24%

02/06/20	HemaCare Corporation Adds GMPrime Cryopreserved Leukopak to its GMP Product Portfolio	CI
22/01/20	MicroMedicine and HemaCare Announces Cooperative Efforts to Improve Cell Therapy Starting Materials	CI

Valuation: HemaCare Corporation

Market Cap	346M 304M 282M 260M 487M 33.48B 496M 3.38B 1.32B 16.33B 1.3B 1.27B 56.65B	P/E 2017	8.18x	P/E 2018	27.6x
Enterprise Value	336M 295M 274M 252M 473M 32.52B 482M 3.28B 1.28B 15.86B 1.26B 1.23B 55.03B	EV / Sales 2017	1.29x	EV / Sales 2018	4.03x
Free-Float	94.17%	Yield 2017 *	-	Yield 2018	-

* Estimated data More valuation ratios

Latest news : HemaCare Corporation

02/06/20	HemaCare Corporation Adds GMPrime Cryopreserved Leukopak to its GMP Product Portfolio	CI
22/01/20	MicroMedicine and HemaCare Announces Cooperative Efforts to Improve Cell Therapy Starting Materials	CI
03/01/20	Charles River Laboratories International, Inc. completed the acquisition of HemaCare Corporation.	CI
16/12/19	Charles River Laboratories International, Inc. entered into a definitive agreement to acquire HemaCare Corporation for approximately $380 million.	CI
19/11/19	HemaCare Expands Its Product Portfolio with GMPrime™ Bone Marrow Aspirate	CI
27/08/19	HemaCare Corporation and Vital River Partner to Provide Human-Derived Biological Material to China	CI
20/08/19	Hemacare Corporation Reports Earnings Results for the Half Year Ended June 30, 2019	CI
26/03/19	HemaCare Corporation Reports Earnings Results for the Year Ended December 31, 2018	CI
20/12/18	HemaCare Corporation announced that it has received $4.999999 million in funding from OBF Investments LLP	CI
06/12/18	HemaCare Corporation Moves its Global Headquarters to Northridge, California	CI
14/11/18	HemaCare Corporation Provides Starting Material for Three FDA Approved Cellular Therapies	CI
21/08/18	HemaCare Corporation Reports Unaudited Earnings Results for the Six Months Ended June 30, 2018	CI
17/07/18	HemaCare Corporation Announces Executive Appointments	CI

More news

Press Releases: HemaCare Corporation

16/12/19

HEMACARE ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of HEMA and Encourages Investors to Contact the Firm

More press releases

Managers and Directors: HemaCare Corporation

Manager	Title	Age	Since
Colin S. Dunn CEO	Chief Executive Officer	-	-
Samira Amini DFI	Director of Finance/CFO	-	-
Maria Pia Muniz COO	Chief Operating Officer	-	01/01/2003

Director	Title	Age	Since
Colin S. Dunn BRD	Director/Board Member	-	-
Samira Amini BRD	Director/Board Member	-	-
Emily Nekimken BRD	Director/Board Member	-	-

More insiders

Other Healthcare Facilities & Services

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HEMACARE CORPORATION	-.--%	+0.08%	-	-	346M
CVS HEALTH CORPORATION	-0.49%	+0.37%	+72.82%	+40.74%	138B
HCA HEALTHCARE, INC.	+1.25%	-2.40%	+6.58%	+32.02%	82.5B
FRESENIUS SE & CO. KGAA	-1.65%	+2.59%	+2.71%	+50.51%	28.01B
QUEST DIAGNOSTICS INCORPORATED	+8.61%	+8.83%	+33.68%	+58.24%	23.23B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+1.32%	+1.27%	-14.30%	-29.20%	19.79B
TENET HEALTHCARE CORPORATION	+1.88%	-0.09%	+25.72%	+158.84%	16.83B
DAVITA INC.	+0.94%	+0.11%	+54.82%	+129.45%	14.9B
REDE D'OR SÃO LUIZ S.A.	-2.38%	-6.13%	+1.72%	-6.24%	14.98B
FRESENIUS MEDICAL CARE AG	+0.58%	+2.07%	-5.70%	-12.01%	12.96B
Average	+0.94%	+0.75%	+19.78%	+46.93%	35.14B
Weighted average by Cap.	+0.54%	+0.93%	+35.21%	+42.16%

See all sector performances

Charles River Laboratories Cell Solutions, Inc. is a cell sourcing provider for developers of cell therapies and basic research. The Company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. It offers a comprehensive and integrated portfolio of drug development products and services available from a single global provider, spanning the continuum from early research to the support of marketed products. Its products and services include Research Models & Services, Discovery Services Safety Assessment, Laboratory Sciences, Cell and Gene Therapy CDMO Solutions, Biologics Testing Solutions, Avian Vaccine Services, QC Microbial Solutions, Scientific & Regulatory Advisory Services, and Scientific Staffing, Training & Operations Support.

Employees

Sector

Healthcare Facilities & Services

More about the company

Stock Market
Stocks
HEMA Stock

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

	2017	2018
Net sales	20.21M 17.78M 16.51M 15.19M 28.48M 1.96B 28.99M 197M 77.03M 955M 75.88M 74.24M 3.31B	28.51M 25.07M 23.29M 21.42M 40.17M 2.76B 40.89M 279M 109M 1.35B 107M 105M 4.67B
Net income	4.43M 3.9M 3.62M 3.33M 6.25M 429M 6.36M 43.3M 16.89M 209M 16.64M 16.28M 726M	4.52M 3.97M 3.69M 3.39M 6.36M 437M 6.48M 44.12M 17.21M 213M 16.95M 16.59M 740M
Net Debt	-9.06M -7.97M -7.4M -6.81M -12.77M -877M -13M -88.51M -34.52M -428M -34.01M -33.27M -1.48B	-9.9M -8.7M -8.09M -7.44M -13.95M -958M -14.2M -96.7M -37.72M -467M -37.16M -36.35M -1.62B

HemaCare Corporation Stock

Stocks

HEMA

US4234981045

Healthcare Facilities & Services

Valuation: HemaCare Corporation

Latest news : HemaCare Corporation

Press Releases: HemaCare Corporation

Managers and Directors: HemaCare Corporation

Other Healthcare Facilities & Services

Financials

Company Profile